Akèy › Ipètansyon Okilè
Etid klinik pou Ipètansyon Okilè ap rekrite nan Etazini
21 etid pou Ipètansyon Okilè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
iDose TR Administration in an Office-Based Surgery Setting
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07816692REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07675824A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07661329Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07075718Clarifying the Optimal Application of SLT Therapy Trial
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT04967989Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT04401982Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT07588152Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT0740815424-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou May 1, 2026 · NCT07325240DSLT for Reducing Medication in Glaucoma
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Apr 20, 2026 · NCT07390890Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Mar 30, 2026 · NCT07495852Automated Applanation Tonometry - Updated
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Mar 6, 2026 · NCT07298356Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 5, 2026 · NCT07217678Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 27, 2026 · NCT07400926Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
Ap rekriteFaz 4
Laj 45 ak plis · Tout sèks · Mizajou Jan 21, 2026 · NCT06848946Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Dec 29, 2025 · NCT06629649Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
Ap rekriteFaz 3
Laj 22 ak plis · Tout sèks · Mizajou Oct 20, 2025 · NCT07218796Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
Ap rekriteFaz 3
Laj 22 ak plis · Tout sèks · Mizajou Oct 20, 2025 · NCT07218783A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2025 · NCT07076303Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2023 · NCT05844384Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2022 · NCT05401357Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.